Enlisting an integrated suite of
cutting-edge preclinical tools
to direct clinical development.
WATERTOWN, Mass. – April 29, 2013 – FORMA Therapeutics Holdings, LLC (FORMA) today announced a strategic collaboration agreement with Celgene Corporation under which FORMA and Celgene will discover, develop and commercialize drug candidates to regulate protein homeostasis targets.
Dr. Kenneth Bair, FORMA's CSO and Head of Research and Development, states, “This collaboration enables us to demonstrate the power of integrating FORMA’s drug discovery engine with the innovative translational science of Daniel D. Von Hoff, M.D., F.A.C.P., and his colleagues at TD2 to advance a broad pipeline of novel therapies. Further, protein homeostasis represents a new area of promising drug development after years of targeting kinase family proteins. This significant drug development collaboration has the potential to bring new drugs against novel targets and address unmet medical needs in the treatment of many cancers.”
For full press release click here.
